Effect of benazepril on survival and cardiac events in dogs with asymptomatic mitral valve disease: A retrospective study of 141 cases

Journal of Veterinary Internal Medicine

Volumn 22, Issue 4, 2008, Pages 905-914

  Pouchelon, J L ^a,b   Jamet, N ^a   Gouni, V ^a,b   Tissier, R ^b,c   Serres, F ^a   Carlos Sampedrano, C ^a,b   Castaignet, M ^a   Lefebvre, H P ^d   Chetboul, Valérie ^a,b,e  

^a Unité de Cardiologie d'Alfort

^b INSERM   (France)

^c ECOLE NATIONALE VÉTÉRINAIRE D ALFORT   (France)

^d UNIVERSITÉ DE TOULOUSE   (France)

^e VIM CA (Cardiology)   (France)

Author keywords

Angiotensin converting enzyme inhibitor; Canine; Doppler; Echocardiography; Regurgitation

Indexed keywords

BENAZEPRIL; BENZAZEPINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANIMAL; ANIMAL DISEASE; ARTICLE; DOG; DOG DISEASE; FEMALE; LONGEVITY; MALE; MITRAL VALVE REGURGITATION; RETROSPECTIVE STUDY;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BENZAZEPINES; DOG DISEASES; DOGS; FEMALE; LONGEVITY; MALE; MITRAL VALVE INSUFFICIENCY; RETROSPECTIVE STUDIES;

ANIMALIA; CANIS FAMILIARIS;

EID: 47849087891     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2008.0105.x     Document Type: Article

References (43)

1. The COVE Study Group. Controlled clinical evaluation of enalapril in dogs with heart failure: Results of the cooperative veterinary enalapril study group. J Vet Intern Med 1995;9:243-252.
2. Ettinger SJ, Benitz AM, Ericsson GF, et al. Effects of enalapril maleate on survival of dogs with naturally acquired heart failure. J Am Vet Med Assoc 1998;213:1573-1577.
3. Pouchelon JL, Martignoni L, King JN, et al. The BENCH Study Group. The effect of benazepril on survival times and clinical signs of dogs with congestive heart failure: Results of a multicenter, prospective, randomised, double-blinded, placebo-controlled, long-term clinical trial. J Vet Cardiol 1999;1:7-18.
4. Pouchelon JL, King JN, Martignoni L, et al. Long-term tolerability of benazepril in dogs with congestive heart failure. J Vet Cardiol 2004;6:7-13.
5. Amberger C, Chetboul V, Bomassi E, et al. Comparison of the effects of imidapril and enalapril in a prospective multicentric randomized trial in dogs with naturally acquired heart failure. J Vet Cardiol 2004;6:9-16.
6. Besche B, Chetboul V, Lachaud Lefay MP, et al. Clinical evaluation of imidapril in congestive heart failure in dogs: Results of the EFFIC study. J Small Anim Pract 2007;48:265-270.
7. Lefebvre HP, Brown SA, Chetboul V, et al. Angiotensin-converting enzyme inhibitors in veterinary medicine. Curr Pharm Des 2007;13:1347-1361.
8. Atkins CE, Brown WA, Coats JR, et al. Effects of long-term administration of enalapril on clinical indicators of renal function in dogs with compensated mitral regurgitation. J Am Vet Med Assoc 2002;221:654-658.
9. Atkins CE, Keene BW, Brown WA, et al. Results of the veterinary enalapril trial to prove reduction in onset of heart failure in dogs chronically treated with enalapril alone for compensated, naturally occurring mitral valve insufficiency. J Am Vet Med Assoc 2007;231:1061-1069.
10. Kvart C, Häggström J, Pedersen HD, et al. Efficacy of enalapril for prevention of congestive heart failure in dogs with myxomatous valve disease and asymptomatic mitral regurgitation. J Vet Intern Med 2002;16:80-88.
11. Lord P, Eriksson A, Häggström J, et al. Increased pulmonary transit times in asymptomatic dogs with mitral regurgitation. J Vet Intern Med 2003;17:824-829.
12. Chetboul V, Lefebvre HP, Carlos Sampedrano C, et al. Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease: A prospective, controlled, blinded, and randomized study. J Vet Intern Med 2007;21:742-753.
13. Toutain PL, Lefebvre HP. Pharmacokinetics and pharmacokinetic/ pharmacodynamic relationships for angiotensin-converting enzyme inhibitors. J Vet Pharmacol Ther 2004;27:515-525.
14. Chetboul V, Carlos Sampedrano C, Concordet D, et al. Use of quantitative two-dimensional color tissue Doppler imaging for assessment of left ventricular radial and longitudinal myocardial velocities in dogs. Am J Vet Res 2005;66:953-961.
15. International Small Animal Cardiac Health Council. Appendix A. Recommendations for diagnosis of heart disease and treatment of heart failure in small animals. In: Fox PR, Sisson D, Moïse NS, eds. Textbook of Canine and Feline Cardiology, 2nd ed. Philadelphia, PA: WB Saunders; 1999:883-901.
16. Helmcke F, Nanda NC, Hsiung MC, et al. Color Doppler assessment of mitral regurgitation with orthogonal planes. Circulation 1987;75:175-183.
17. Muzzi RAL, De Araùjo RB, Muzzi LAL, et al. Regurgitant jet area by Doppler color flow mapping: Quantitative assessment of mitral regurgitation severity in dogs. J Vet Cardiol 2003;5:33-38.
18. Chetboul V, Athanassiadis N, Concordet D, et al. Observer-dependent variability of quantitative clinical endpoint: Example of canine echocardiography. J Vet Pharmacol Therap 2004;27:49-56.
19. Thomas WP, Gaber CE, Jacobs GJ, et al. Recommendations for standards in transthoracic two-dimensional echocardiography in the dog and cat. Echocardiography Committee of the Specialty of Cardiology, American College of Veterinary Internal Medicine. J Vet Intern Med 1993;7:247-252.
20. Gouni V, Serres FJ, Pouchelon JL, et al. Quantification of mitral valve regurgitation in dogs with degenerative mitral valve disease by use of the proximal isovelocity surface area method. J Am Vet Med Assoc 2007;231:399-406.
21. Johnson L, Boon J, Orton EC. Clinical characteristics of 53 dogs with Doppler-derived evidence of pulmonary hypertension: 1992-1996. J Vet Intern Med 1999;13:440-447.
22. Kittleson MD, Kienle RD. Pulmonary arterial and systemic arterial hypertension. In: Kittleson MD, Kienle RD, eds. Small Animal Cardiovascular Medicine. Saint Louis, MO: Mosby; 1998:433-449.
23. Lefebvre HP, Laroute V, Concordet D, et al. Effects of renal impairment on the disposition of orally administered enalapril, benazepril, and their active metabolites. J Vet Intern Med 1999;13:21-27.
24. Toutain PL, Lefebvre HP, Laroute V. New insights on effect of kidney insufficiency on disposition of angiotensin-converting enzyme inhibitors: Case of enalapril and benazepril in dogs. J Pharmacol Exp Ther 2000;292:1094-1103.
25. Serres F, Chetboul V, Tissier R, et al. Chordae tendineae rupture in dogs with degenerative mitral valve disease: Prevalence, survival, and prognostic factors (114 cases, 2001-2006). J Vet Intern Med 2007;21:258-264.
26. Serres FJ, Chetboul V, Tissier R, et al. Doppler echocardiography-derived evidence of pulmonary arterial hypertension in dogs with degenerative mitral valve disease: 86 cases (2001-2005). J Am Vet Med Assoc 2006;229:1772-1778.
27. Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, et al. Quantitative determinants of the outcome of asymptomatic mitral regurgitation. N Engl J Med 2005;352:875-883.
28. Zoghbi WA, Enriquez-Sarano M, Foster E, et al. American Society of Echocardiography. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003;16:777-802.
29. Grigioni F, Enriquez-Sarano M, Zehr KJ, et al. Ischemic mitral regurgitation: Long-term outcome and prognostic implications with quantitative Doppler assessment. Circulation 2001;103:1759-1764.
30. Lee R, Haluska B, Leung DY, et al. Functional and prognostic implications of left ventricular contractile reserve in patients with asymptomatic severe mitral regurgitation. Heart 2005;91:1407-1412.
31. Gaasch WH, John RM, Aurigemma GP. Managing asymptomatic patients with chronic mitral regurgitation. Chest 1995;108:842-847.
32. Iung B, Gohlke-Barwolf C, Tornos P, et al. (Working Group on Valvular Heart Disease). Recommendations on the management of the asymptomatic patient with valvular heart disease. Eur Heart J 2002;23:1252-1266.
33. Botkin NF, Seth PS, Aurigemma GP. Asymptomatic valvular disease: Who benefits from surgery? Curr Cardiol Rep 2005;7:87-93.
34. Sampaio RO, Grinberg M, Leite JJ, et al. Effect of enalapril on left ventricular diameters and exercise capacity in asymptomatic or mildly symptomatic patients with regurgitation secondary to mitral valve prolapse or rheumatic heart disease. Am J Cardiol 2005;96:117-121.
35. Calabro R, Pisacane C, Pacileo G, et al. Hemodynamic effects of a single oral dose of enalapril among children with asymp-tomatic chronic mitral regurgitation. Am Heart J 1999;138(Part 1):955-961.
36. Chetboul V, Tissier R, Villaret F, et al. Epidemiological, clinical, echo-Doppler characteristics of mitral valve endocardiosis in Cavalier King Charles in France: A retrospective study of 451 cases (1995 to 2003). Can Vet J 2004;45:1012-1015.
37. Kvart C, Häggström J. Acquired valvular heart disease. In: Ettinger SJ, Feldman EC., eds. Textbook of Veterinary Internal Medicine, 5th ed. Philadelphia, PA: WB Saunders; 2000:787-800.
38. Serfass P, Chetboul V, Carlos Sampedrano C, et al. Retrospective study of 942 small sized-dogs: Prevalence of left apical systolic heart murmur and left-sided heart failure, critical effects of breed, and sex. J Vet Cardiol 2006;8:11-18.
39. Nicolle AP, Chetboul V, Allerheiligen T, et al. Azotemia and glomerular filtration rate in dogs with chronic valvular disease. J Vet Intern Med 2007;21:943-949.
40. Brands MW, Magdalena AG, Mizelle HL, et al. Chronic angiotensin- converting-enzyme inhibition improves cardiac output and fluid balance during heart failure. Am J Physiol 1993;264:414-422.
41. Zuccala G, Onder G, Marzetti E, et al. GIFA Study Group. Use of angiotensin-converting enzyme inhibitors and variations in cognitive performance among patients with heart failure. Eur Heart J 2005;26:226-233.
42. Rodriguez-Yanez M, Castellanos M, Blanco M, et al. Vascular protection in brain ischemia. Cerebrovasc Dis 2006;21(Suppl 2):21-29.
43. Bongartz LG, Cramer MJ, Doevendans PA, et al. The severe cardiorenal syndrome: 'Guyton revisited.' Eur Heart J 2005;26: 11-17.